UK patients enabled access to transformative new medicines in shortest time possible via new, integrated Innovative Licensing and Access Pathway
It is the only example globally of an end-to-end access pathway, where a medicine developer can work collaboratively with the national health system, the regulator, and health technology assessment bodies from the early stages of clinical development.
Continue reading this article about UK patients enabled access to transformative new medicines in shortest time possible via new, integrated Innovative Licensing and Access Pathway
by Medicines and Healthcare products Regulatory Agency
NHS Forums - For daily discussion by NHS Staff.

It is the only example globally of an end-to-end access pathway, where a medicine developer can work collaboratively with the national health system, the regulator, and health technology assessment bodies from the early stages of clinical development.
Continue reading this article about UK patients enabled access to transformative new medicines in shortest time possible via new, integrated Innovative Licensing and Access Pathway
by Medicines and Healthcare products Regulatory Agency
NHS Forums - For daily discussion by NHS Staff.